Scynexis builds out case for its antifungal in the hospitalized setting, but investors don't seem happy
The antifungal work at Scynexis is not abating. Looking to expand beyond its initial June 2021 nod for treating vaginal yeast infection, the biotech has new data on oral ibrexafungerp for hospitalized patients with difficult-to-treat and refractory fungal infections.
The New Jersey biotech said data from 47 newly evaluable patients across two Phase III trials of the drug, the fourth interim analysis out of the studies, showed oral ibrexafungerp’s potential in filling a “significant need for a new antifungal therapy,” according to medical chief David Angulo. But investors thought differently and sent shares $SCYX tumbling 20% after the opening bell Friday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.